Increased deaths may hang up Novartis' panobinostat at ODAC
This article was originally published in Scrip
Executive Summary
FDA drug reviewers on 4 November raised concerns about an increased incidence of deaths due to causes other than disease progression with Novartis' experimental multiple myeloma drug panobinostat – 7% versus 3.5% for placebo.